Zydus Lifesciences has entered into First Amendment agreement to the Share Purchase, Subscription and Shareholder’s Agreement (SPSSA) on November 2, 2022 to acquire additional stake of 0.31% on a fully diluted basis in AMP Energy Green Nine (AMP), resulting into aggregate stake of 12.17% on a fully diluted basis in AMP. Earlier, the company had entered into Share Purchase, Subscription and Shareholder’s Agreement to acquire upto 11.86% stake on a fully diluted basis in AMP Energy Green Nine.
In line with the Company’s commitment to enhance the share of renewable power source in its operation and to comply with regulatory requirement for being a captive user under Electricity Laws, 2003, the Company will acquire up to 12.17% stake, in one or more tranches, on fully diluted basis in AMP throughout the term of the definitive agreements i.e., Power Purchase Agreement, SPSSA and First Amendment Agreement to SPSSA.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: